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Abstract: Tuberculosis is one of the most devastating bacterial diseases, with increasing rates of morbidity and mortality,
despite the presence of effective chemotherapy and Bacillus-Calmette-Guerin (BCG) vaccine. The success of
Mycobacterium tuberculosis lies in its ability to spread by aerosol droplets, evade the host immune system and to persist
in pulmonary granulomas. The advancement in the field of molecular and cellular microbiology and the availability of
transcriptome and proteome data of M. tuberculosis have aided in understanding the pathogenesis of this organism for
developing more effective drugs. The current strategy of drug design is to identify gene products, which are essential for
survival and virulence. To date, several gene products of mycobacteria, ranging from proteins involved in cell wall
synthesis to energy generation and from entry into host to persistence, have been shown to be essential for the survival or
virulence of M. tuberculosis. These proteins and their associated pathways are considered as promising drug targets
against M. tuberculosis and several of these have been patent protected. Herein, we enlist drug targets against M.
tuberculosis for which patents have been filed and issued during the last ten years. The significance of these drug targets
in the development of drug is also discussed. This review presents a comprehensive account of the pivotal information for
drug discovery and drug design to all researchers involved in tuberculosis research.
Keywords: Mycobacterium tuberculosis, tuberculosis, drugs, cell envelope, MabA, sigma factor, RNA polymerase, signal
transduction, serine/threonine kinases, metabolism, virulence, isocitrate lyase, dormancy.
INTRODUCTION
Tuberculosis, caused by Mycobacterium tuberculosis,
remains one of the biggest killers amongst the infectious
diseases despite the availability of effective drugs and an
attenuated Bacillus-Calmette Guerin (BCG) vaccine.
Streptomycin was the first drug introduced in 1944 for the
treatment of tuberculosis but almost immediately after its
introduction many patients started showing resistance to this
antibiotic [1-3]. Para-aminosalicylate (PAS) was introduced
in 1946 that largely overcame the emergence of resistant
strains [4]. A few years later, isoniazide (INH) was develo-
ped and initial treatment with both INH and streptomycin
was even more effective. To date, many drugs are available,
which are classified into two categories. First line therapy
includes five medications: isoniazide (isonicotinic acid
hydrazide), pyrazinamide (analog of nicotinamide), etham-
butol [(S,S´)-2,2´(ethylenediimino)di-1-butanol], rifampicin
(lipophilic ansamycine) and streptomycin (aminocyclitol
glycoside) [5, 6]. Second line therapy, which is used except-
ionally in the cases of drug resistance, includes cycloserine,
capreomycin, fluoroquinolones, ethionamide, PAS, thioace-
tazone, rifabutin, clofazimine and some macrolides [7].
The major setback in controlling tuberculosis was the
emergence of multidrug resistant tuberculosis (MDR-TB)
during 1990-92. Currently, at least 50 million people are
estimated to be affected with MDR-TB. A few MDR strains
of M. tuberculosis were found to be resistant to many first
line agents as well as some of the second line drugs [8].
Moreover, the high rate of coinfection with human
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immunodeficiency virus (HIV) presented a challenge to the
existing chemotherapies. One of the limitations of currently
available drugs is their inability to act on latent bacilli.
People carrying latent infection are at a risk of reactivation
and this is one of the major barriers in controlling
tuberculosis. Therefore, there is an urgent need to develop
novel drugs that can act against both actively growing and
dormant bacteria. The efforts for drug development are being
coordinated by Global Alliance for TB Drug Development
(www.tballiance.org), an organization that has been involved
in developing public-private partnerships to bring out new,
faster-acting and affordable drugs against tuberculosis.
Rational development of a new antitubercular agent
requires the exploration of new means to understand the
genetics and physiology of M. tuberculosis. In this regard,
availability of the genome sequence of M. tuberculosis [9]
and powerful genetic tools for manipulating mycobacteria
have provided valuable information about the potential
targets. Also, the information available from X-ray
crystallographic studies of many of these targets has helped
in designing novel chemotherapeutic agents. This review
exclusively focuses on mycobacterial targets that have been
patent protected from all over the world in the last ten years,
Fig. (1). Herein, we present the information vis-à-vis
proteins that are important for the survival of M. tuberculosis
during infection and persistence in the host environment.
The potential drug targets compiled in this review are likely
to lead to new medication that should facilitate in controlling
the spread of tuberculosis.
PATENT PROTECTED DRUG TARGETS
A patent is a set of exclusive territorial rights granted by
the government of a country to the assignee for their creative
ideas and expressions of the human mind that have
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commercial value. At present, several gene products, which
are part of many important pathways such as cellular
metabolism, transcription, translation, cell envelope
synthesis, signal transduction, persistence and virulence have
been patented owing to their importance as promising drug
targets (Table 1).
PROTEINS INVOLVED IN CELL ENVELOPE
METABOLISM
Mycobacteria belong to a suprageneric taxon, the
mycolata, which also includes Corynebacteria, Nocardiae
and Rhodococci, by virtue of similarity in their cell wall
architecture [10]. The mycobacterial cell envelope is a
complex structure comprising mycolic acids covalently
bound to peptidoglycan via arabinogalactan [11]. The cell
wall of M. tuberculosis confers resistance against many
antibacterial agents known to inhibit cell wall synthesis such
as isoniazide, ethionamide, isoxyl, and the thiosemicar-
bazones. An enriched knowledge of the biosynthesis and
assembly of the cell envelope components has provided vital
clues for the development of novel antimycobacterial agents.
After phagocytosis by macrophages, M. tuberculosis
overcomes several environmental stresses, such as those
caused by toxic reactive oxygen and nitrogen species. The
detrimental effect of the reactive radicals is circumvented by
modifications such as cyclopropanation of mycolic acids,
which renders mycobacterium resistant to lipid peroxidation
[11]. Mycolic acid cyclopropanating enzyme (MACE,
US5573915) [12], also known as cyclopropane mycolic acid
synthase (cma) is responsible for cyclopropanation at distal
position of the mero chain in the a-mycolic acid series [13].
Non-pathogenic mycobacteria, M. smegmatis do not cyclo-
propanate their mycolic acids. Heterologous expression of
cma in M. smegmatis not only resulted in cyclopropana-tion
of a-mycolates but also significantly protected recombinant
M. smegmatis from oxidative stress [13]. A homolog of cma
is also present in M. leprae, suggesting that cyclopropanation
of mycolic acids is specific to pathogenic forms of
mycobacteria [14]. Therefore, therapeutic agents, which
affect the activity of MACE, hold the key to successful
elimination of pathogenic mycobacteria. PCT patent
numbers WO9638581 and US5573915 issued in
Fig. (1). An outline of Patent Protected drug targets of Mycobacterium tuberculosis.
 The patented targets against which antitubercular drugs can be developed are shown in boxes. These targets are known to control various
cellular processes required for survival or virulence of M. tuberculosis. The site of action of first line drugs (Rifampicin, Isoniazid,
Pyrazinamide, Ethambutol and Streptomycin) are shown by arrows.
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Table 1. Patent Protected Drug Targets of M. tuberculosis
S. No.  DRUG TARGET CLASSIFICATION PATENT NUMBERa  PDB ID
1 Arylamine N-acetyl tranferases Cellular Metabolism
EP1082441, EP2002516109T,
WO9961625, GB9811407
1GX3
2
Proteasome associated genes and
DNA repair genes
Cellular Metabolism US2004213776 –
3
Acetolactate synthase and ketol acid
reducto isomerase
Cellular Metabolism
AU2451397, US5998420,
WO9737660
–
4 Thymidylate synthase Cellular Metabolism WO02072805, GB0105763D –
5 SigA and SigB Transcription
AU706367, AU4550896,
AU5018496, CA2171600,
CN1201465, EP0832116,
GB2298862, IE960132,
JP2000503525, NZ286081,
WO9638478, SE9501976,
SE9502596, SE9503246,
–
6 SigF, OrfX, and OrfY Transcription
AU732858, AU2580297,
CA2249208, EP0910403,
JP2000508525T, US5700925,
US5824546, US6004764,
WO9735611
–
7 AlgU Transcription
CA2278314, EP0970192,
JP200150903, US6355469,
WO9831789 
–
8 RNA Polymerase alpha-subunit Transcription
AU7625298, CA2274098,
EP0956347, EP2001505438,
US6355464, WO9824891
–
9 WhiB1, WhiB2, WhiB3 and WhiB4 Transcription
EP1245683, US6645505,
US2002164573 
–
10 Adenylyl cyclase Signal Transduction
CA2447110, EP1258528, EP1390487,
US2005048603, WO02092805
Crystallization done, No
PDB ID availableb
11 Protein kinase B, G, H and J Signal Transduction AU2003206594, WO03074728 1MRU
12 Tyrosine phosphatases Signal Transduction WO2005005639 1U2Q
13 DevR Signal Transduction EP1472339, GB2398302, WO03066838 –
14 Isoleucyl tRNA synthase Translation US5756327 _
15 Methionyl tRNA synthase Translation US5798240 _
16 Seryl tRNA synthase Translation US5656470    –
17 MabA (FabG1) Cell Envelope
AU2003258723, EP1490491,
FR2837836, WO03082911 
1UZN
18 EmbC, EmbA, and EmbB Cell Envelope AU6467598, US6015890, WO9841533 _
19 MACE Cell Envelope AU5881496, US5573915, WO9638581 1L1E
20 D-alanine racemase Cell Envelope US2003133952 –
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(Table 1) Contd….
S. No. DRUG TARGET CLASSIFICATION PATENT NUMBERa  PDB ID
21  Rv3133c, Rv2623, Rv2626c Dormancy Related Genes
AU1610002, GB0030368, GB2386420,
US2004242471, WO0248391 
_
22 Resuscitation Factor (RpfA-E) Dormancy Related Genes
AU749414, AU7779798, CA2292898,
EP0983361, GB9711389, GB9811221,
JP2002503106, NZ501568,
WO9855624, ZA9804838
1XSF
23 Rv1174c and phospholipids Dormancy Related Genes WO0245736 _
24 Isocitrate lyase Dormancy Related Genes
AU3391602, US2003018166,
WO0233118
1F8M, 1F8I
25
Alkyl hydroperoxide reductase
(AhpC)
Virulence WO9954479 2BMX
26
AhpD, dihydrolipoamide
dehydrogenase, and dihydrolipoamide
succinyltransferase
Virulence US2003190325 1KNC
27 SecA Virulence AU5170896, US5885828, WO9626276 1NL3, 1NKT
a The first two letters in the patent number corresponds to PCT (Patent Corporation Treaty) contracting states: AU, Australia; AT, Austria; CA, Canada; CH, Switzerland; CN, China;
DE, Germany; FR, France; EP, Europe; GB, Great Britain; IE, Ireland; JP, Japan; NZ, New Zealand; SE, Sweden; TW, Taiwan; US, United States of America; WO, World
Intellectual Property Organization; ZA, South Africa.
bwww.doe-mbi.ucla.edu/TB/
1996, relate to MACE and its DNA or protein compositions
useful for both diagnosis and designing of therapeutics for
treatment of tuberculosis and other mycobacterial infections.
The patent discloses the invention of a method for
determining the ability of a compound to inhibit the cyclo-
propanation of mycolic acids in pathogenic mycobacteria.
MabA, a NADPH-dependent b -ketoacyl ACP reductase,
is involved in the biosynthesis of long chain fatty acids, the
precursors of mycolic acids (WO03082911) [15]. Unlike
mabA of M. smegmatis, mabA of M. tuberculosis is in an
operon with inhA, an NADH-dependent 2-trans-enoyl ACP
reductase [16]. Both genes together with KasA/B ( b -ketoacyl
synthase) form type II fatty acid elongation system (FAS-II)
[17-19]. INH is known to inhibit InhA and MabA by
formation of a covalent adduct between MnIII-activated
isoniazid and the MabA/InhA cofactor [20]. Crystal structure
analysis revealed that MabA has specific functional and
structural properties when compared to other homologous
bacterial b -ketoacyl reductases, such as large hydrophobic
substrate binding pocket and preference for long chain
substrates [21]. These distinct properties of MabA make it a
potential drug target specific for mycobacteria. Also, the
mechanism of inhibition by a metabolite of INH could serve
as a model for rational drug designing. WO03082911
published in 2004 relates to the recombinant native and
mutant protein MabA. The invention provides crystallo-
graphic co-ordinates for designing and screening ligands
inhibiting the enzymatic activity of MabA.
Ethambutol (EMB) is a frontline antituberculosis drug,
which targets the mycobacterial cell wall. Resistance to
EMB was used as a tool to identify genes participating in
cell wall biosynthesis, which led to the identification of
mycobacterial embCAB gene cluster (US6015890) compri-
sing embC, embA and embB genes [22-24]. EmbA and
EmbB are arabinosyl transferases, which utilize
arabinofuranosyl phosphodecaprenol for arabinosylation of
cell wall arabinogalactan, the major polysaccharide of the
mycobacterial cell wall [25-27]. Over expression of Emb
proteins [23] and mutations of conserved residue Met306 are
associated with resistance to EMB in mycobacteria [22, 23,
28]. Identification and characterization of resistance to EMB
has provided information for development of new
chemotherapeutic agents against these mutated Emb
proteins. WO9841533 published in 1998 and US6015890
issued in 2000 relate to the identification, cloning,
sequencing and characterization of the embCAB operon. This
patent also provides one or more single-stranded nucleic acid
probes, which specifically hybridize to the wild type
embCAB operon or the mutated embCAB operon that may be
used in the diagnosis of drug-resistant mycobacterial strains.
D-Alanine is an essential component of dipeptide D-
alanyl-D-alanine, involved in the cross-linking of peptido-
glycan strands in bacteria [29]. D-alanine racemase (alrA)
catalyzes the conversion of L-alanine into D-alanine [30],
and D-alanine-D-alanine ligase catalyzes the subsequent
dimerization of D-alanine into the key dipeptide, D-alanyl-
D-alanine [31]. Inactivation of D-alanine racemase was
shown to affect the survival of M. smegmatis in phagocytic
cells (US2003133952) [32]. Thus, inhibitors can be designed
against D-alanine racemase as novel antituberculosis drugs
targeting peptidoglycan biosynthesis in mycobacteria.
US2003133952 published in 2003 relates to methods of
making live-attenuated vaccines against pathogenic
mycobacteria using alrA mutants. Furthermore, alrA mutants
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can be used for screening antimycobacterial agents that are
synergistic with peptidoglycan inhibitors.
PROTEINS EMPLOYED IN TRANSCRIPTION AND
TRANSLATION
Genes required for survival following uptake by
macrophages can provide insight into mycobacterial
pathogenesis and provide novel targets for developing
antibacterial agents. The ability to adapt to intracellular
stress requires regulation of complex gene expression
mediated mainly by sigma factors. Sigma factors are
involved in transcription initiation by interacting with RNA
polymerase. DNA-dependent RNA polymerase is a basic
unit of the bacterial transcription apparatus. The holoenzyme
is a complex consisting of five protein subunits: two copies
of a  subunit and one copy each of b , b ' and sigma subunit.
The b  and b ' subunits are invariant in a given bacterial
species and together with a  subunit form core RNA
polymerase. The a  subunit is involved in protein-protein
interactions with transcription activators and protein-DNA
interactions [33-35]. The amino terminal domain of a
subunit is also required for the assembly of core RNA
polymerase. RNA polymerase is a well-documented drug
target and rifampicin is a highly specific inhibitor of
mycobacterium RNA polymerase [36]. Due to emergence of
resistant strains, development of new compounds that
interfere with the enzymatic activity of RNA polymerase or
disrupt interaction of a subunit with the core enzyme is
urgently required. Healy et al., have patented the method for
high-throughput screening of RNA polymerase inhibitors
and identified anti-tuberculosis compounds that specifically
inhibit mycobacterial transcription (EP0956347) [37]. Patent
applications WO9824891 published in 1998, EP0956347 and
US6355464 issued in 2002 relate to novel nucleic acids
encoding the RNA polymerase alpha subunit from M.
tuberculosis. The invention also provides vectors comprising
the nucleic acids, cells comprising the vectors, and methods
for producing M. tuberculosis alpha subunit.
Sigma factors are interchangeable RNA polymerase
subunits that are responsible for promoter recognition.
Prokaryotes usually have a constitutively expressed principal
sigma factor, which is responsible for the transcription of
essential housekeeping genes, and a number of alternative
sigma factors that are transcriptionally and/or post-
translationally activated in response to specific environmen-
tal signals [38]. Mycobacterial genome encodes at least 14
sigma factors [9]. Sigma factor A (sigA; rpoV),
(WO9638478) [39], a principal sigma factor, is an essential
gene and has been shown to be involved in virulence of M.
tuberculosis [40]. A mutation in sigA from arginine to
histidine at amino acid residue 522 resulted in the loss of
virulence of M. bovis and complementation of the attenuated
M. bovis mutant with the M. tuberculosis wild type sigA
restored virulence [40]. The transcription of sigB
(WO9638478) [39] is regulated differentially from that of
sigA. Transcription of the sigB gene increases significantly
when M. tuberculosis  enters the stationary phase at 10 days
of microaerophilic incubation and under various stress
conditions [41]. These findings suggest that SigB may be an
alternative or secondary sigma factor, which controls a large
stationary-phase regulon.
WO9638478 published in 1996 and GB2298862 issued
in 1999 relate to the provision of novel nucleic acid
molecules coding for SigA and SigB subunits of M.
tuberculosis RNA polymerase. The invention further
provides screening assays for compounds, which inhibit the
interaction between a sigma subunit and a core RNA
polymerase.
sigH, (AlgU, US6355469) [42] was shown to be induced
after heat shock and after exposure to the thiol-specific
oxidizing agent, diamide [43]. M. tuberculosis mutants
lacking sigH showed reduced immunopathology in infected
animals [44]. M. tuberculosis sigF mutant strain was shown
to be attenuated in immunocompetent mice [45, 46] and
moreover, the expression level of sigF is upregulated in
stationary phase and in stress conditions [47]. SigF is
regulated by M. tuberculosis OrfX (anti-sigma factor) and
OrfY (anti-anti-sigma factor) proteins. The M. tuberculosis
SigF, OrfX and OrfY (WO9735611) [48] can be used to
screen for dormancy activators, which trigger growth arrest
during active tuberculosis infection and can also be used to
screen for antagonists that induce reactivation in patients
with latent tuberculosis. Reactivation will render antimyco-
bacterial drugs more effective, because the available drugs
are typically more potent toward actively growing bacilli.
Thus, sigma factors are logical targets for the development
of the transcriptional inhibitors. US6355469 patent issued in
2002 and WO9831789 published in 1998 relate to DNA
encoding M. tuberculosis RNA polymerase AlgU sigma
subunit protein and methods of detecting inhibitors of the
RNA polymerase. The invention also encompasses
sequence-conservative and function-conservative variants of
this sequence. US5700925 patent issued in 1997 is directed
to a gene involved in latency and a diagnostic method for
detecting latent M. tuberculosis. The invention also relates to
M. tuberculosis vaccines expressing mutant sigF genes.
Patent application WO9735611 published in 1997 and
AU732858 patent issued in 2001 disclose a method for
identifying a gene or a protein, which is regulated by a sigma
factor of M. tuberculosis.
WhiB proteins were originally described in Streptomyces
coelicolor and were shown to be involved in sporulation and
cell septation [49]. WhiB family proteins are also present in
M. tuberculosis  and M. bovis BCG. WhiB proteins (WhiB1,
WhiB2, WhiB3 and WhiB4, US6645505) [50] of M.
tuberculosis have been patented and disruption of these
genes in M. bovis BCG revealed that whiB1 is an essential
gene and whiB2, whiB3 and whiB4 are involved in growth
and septum formation. Furthermore, WhiB proteins were
characterized by the yeast two-hybrid system that
demonstrated DNA binding and transcriptional activation
properties of these proteins [50]. WhiB3 has also been
shown to be involved in virulence of M. tuberculosis as gene
inactivation led to reduction in the survival in
immunocompetent mice [51]. Patent number US6645505
issued in 2003 discloses an in vivo drug screening method
taking advantage of the yeast two-hybrid and provides a
method of using whiB genes. The drugs against WhiB2 and
the WhiB4 of M. tuberculosis H37Rv and M. bovis BCG will
be particularly useful where drug resistance has developed
against the WhiB1 and WhiB3 or where the anti-WhiB1 and
anti-WhiB3 drugs are allergic or toxic.
100    Recent Patents on Anti-Infective Drug Discovery, 2006, Vol. 1, No. 1 Vohra et al.
The components of the translational apparatus are
prominent targets for antibiotics. Aminoacyl-tRNA syntheta-
ses catalyze the transfer of specific amino acid to its
corresponding tRNA to form aminoacyl-tRNAs, which are
used during protein synthesis. Eukaryotic-like isoleucyl-
tRNA synthetase (IleRS, US5756327) of M. tuberculosis
[52, 53] has been found to be resistant to the prokaryotic
IleRS-targeted antibiotic, pseudomonic acid [54, 55].
Moreover, M. tuberculosis methionyl-tRNA synthetase
(MetRS, US5798240) [56] has characteristic class I signature
sequences (HVGH and KMSKS) but lacks the Zn2+ binding
motif and the C-terminal dimerization appendix [57].
Because the amino acid sequences of the tRNA synthetases
have diverged with time, significant differences exist
between the structures of the enzymes from mammals and
mammalian pathogens [58]. These differences can be
exploited by identifying inhibitors, which have specific
activity against these mycobacterial tRNA synthetases.
Moreover, the seryl-tRNA synthetase (US5656470) [59] of
M. tuberculosis has also been characterized by biochemical
assays and antisense strategy. US5756327 patent issued in
1998 relates to IleRS [52]. Recombinant DNA constructs
encoding IleRS can be used for the construction of tester
strains to identify inhibitors of the essential tRNA
synthetase. US5798240 patent issued in 1998 relates to the
isolated and/or recombinant nucleic acids, which encode
MetRS [56]. The invention also provides antisense nucleic
acid that can hybridize to the mRNA of MetRS of
mycobacteria. US5656470 patent issued in 1997 relates to
isolated and/or recombinant nucleic acids, which encode
seryl-tRNA synthetases of mycobacterial origin [59].
PROTEINS OF SIGNAL TRANSDUCTION PATH-
WAYS
After entering macrophages, cross-talk modalities exist
between the mammalian host and the pathogen, with the
result that the host’s defense system is bypassed and the
pathogen survives and proliferates. M. tuberculosis genome
encodes 15 putative adenylyl cyclases (ACs), indicating the
presence of signal transduction pathways mediated through
cAMP as a second messenger. It has also been reported that
cAMP levels increase in macrophages infected with
mycobacteria leading to an inhibition of phagosome-
lysosome fusion [60]. Amongst the 15 putative ACs,
Rv2435c and Rv1625c are grouped with mammalian ACs
based on their sequence homology (WO02092805 and
US2005048603) [61, 62]. As the closest progenitor of
mammalian AC, Rv1625c gene product comprises a protein
with six transmembrane helices and a single cytosolic
catalytic domain, which dimerizes to form a 12-
transmembrane, homodimeric enzyme, with two substrate-
binding sites at the dimer interface in contrast to the
heterodimeric mammalian enzyme [63]. Structural and
biochemical analysis revealed that despite the high (60%
similarity to guanylyl cyclases) sequence similarity to the
mammalian enzymes, Rv1625c has a unique substrate
binding pocket that has not been reported in any other
cyclase so far [63, 64]. These differences could in principle
be exploited in designing novel drugs. US2005048603
published in 2005 and WO02092805 published in 2002
relate to a method for expression of membrane proteins
wherein a portion of a nucleotide sequence coding for the
membrane protein is fused to a portion of a nucleotide
sequence coding for an adenylyl cyclase of M. tuberculosis
[61, 62]. The main advantage of this inventive method is that
the recombinant membrane protein can be effectively
expressed in prokaryotic as well as in eukaryotic systems.
The invention further provides a kit for expression of
membrane proteins.
Protein kinases and phosphatases are essential for
virulence in a number of bacterial species that modulate the
host-signaling network. M. tuberculosis has two functional
tyrosine phosphatases, MptpA and MptpB (WO2005005639)
[65], which are secreted into the culture filtrate by actively
growing mycobacterial cells [66]. mptpA and mptpB knock
out strains of M. tuberculosis were attenuated in the lungs
and spleen of infected animals. The ability of mutant strains
to survive in macrophages activated with IFN-g  was highly
impaired [67]. This suggests that tyrosine phosphatases of M.
tuberculosis help in its survival in the host cells by
dephosphorylating proteins that are involved in IFN-g
mediated signaling pathways. WO2005005639 published in
2005 relates to the role of mptpA and mptpB in the virulence
and pathogenesis of mycobacteria. The invention provides
mutant mycobacterium strains harboring a modified tyrosine
phosphatase gene (mptpA or mptpB) wherein the mutant
mycobacterium strain is incapable of expressing the active
tyrosine phosphatase.
Eukaryotic type serine/threonine kinases of M.
tuberculosis [68] are also attractive therapeutic targets.
Because of their significance in signal transduction and their
role in circumventing the hostile environment, many of them
have been patent protected. Mutant strains of protein kinase
G (PknG) [69, 70] and protein kinase H (PknH) were unable
to survive under in vivo conditions (WO03074728) [71].
PknG was shown to be secreted in host cells, causing
phagosomal maturation block [70]. The inhibition of
phagosome-lysosome fusion may be mediated by
phosphorylation of host proteins by PknG. PknH can
phosphorylate EmbR, a protein hypothesized to modulate the
levels of arabinosyltransferases involved in arabinan
biosynthesis of arabinogalactan, a key molecule of the
mycobacterial cell wall [72, 73]. pknB (protein kinase B,
WO03074728) [71], one of the four M. tuberculosis kinases,
conserved in the downsized genome of Mycobacterium
leprae, is presumed to play an important role in the
processes that regulate the complex life cycle of
mycobacteria. Transposon-mutagenesis has shown that PknB
and PknG are required for growth of mycobacterium under
in vitro conditions [74]. PknB inhibitor 1-(5-isoquinoline-
sulfonyl)-2-methylpiperazine (WO03074728) [71, 75] was
found to inhibit the growth of M. bovis (BCG) and M.
smegmatis. WO03074728 published in 2003 relates to a
method for identifying compounds capable of affecting the
activity of serine/threonine kinases (PknB, PknG, PknH and
PknJ) of M. tuberculosis. Knockout mutants of PknG and
PknH display slower growth and viability both in vitro and
in vivo. The compounds of this invention can be incorporated
into a variety of formulations for therapeutic administration.
The two-component system plays a central role in the
adaptation of pathogenic bacteria to the environmental
signals prevailing within host tissues. The genes encoding
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the response regulator DevR (Rv3133c/DosR, EP1472339)
[76] and cytoplasmic region of the histidine kinase DevS
(Rv3132c/DosS), are part of a well characterized two-
component system of M. tuberculosis [77]. Expression of
Rv3134c-devR-devS operon has been shown to be induced
in hypoxic cultures of M. tuberculosis [78]. Guinea pigs
infected with the mutant strain of DevR showed a significant
decrease in gross lesions in lung, liver and spleen compared
to guinea pigs infected with the parental strain [79]. The
mutant strain also showed loss in viability in oxygen
deprived cultures [76]. These observations suggest that
DevR-DevS system is involved in the virulence of M.
tuberculosis and acts as a key regulatory link between
oxygen limitation and the initiation and maintenance of
adaptive response to hypoxia. Therefore, this genetic system
could serve as a vital target for the development of new
drugs for elimination of dormant bacilli. WO03066838
published in 2003 relates to a process for identifying a novel
target for the development of therapeutic modalities and
drugs effective against tuberculosis. The patent relates to
testing of M. tuberculosis devR mutant strain for virulence in
guinea pigs.
ENZYMES INVOLVED IN CELLULAR METABO-
LISM
The proteins involved in metabolic pathways are also
promising targets as they are essential for survival of the
pathogen. Arylamine N-acetyltransferases (NATs,
WO9961625) [80] belong to a unique family of proteins
found in a wide range of organisms, catalyzing the acetyl-
CoA dependent N-acetylation of the arylamines, N and O
acetylation of arylhydroxy amines and acetylation of
aromatic hydrazines. Human NAT2 acetylates and inacti-
vates the antituberculosis drug, isoniazid (INH) and is
polymorphic. A homologue of human NAT2 in M.
tuberculosis has also been shown to acetylate and inactivate
INH in vitro [81]. Introduction of a substrate or an inhibitor,
which may diminish the activity of NAT against INH can act
as an anti-mycobacterial drug. WO9961625 published in
1999 relates to arylamine N-acetyltransferase proteins from
M. tuberculosis and M. smegmatis together with antibodies
raised against these proteins, and methods of detecting
mycobacteria using such antibodies. WO9961625 has also
described the methods for screening compounds that are
ligands of arylamine N-acetyltransferase. Such ligands,
designed using three-dimensional structures of NATs can be
used for treatment of mycobacterial infections.
Microbes synthesize branched-chain amino acids such as
isoleucine, valine and leucine. The three reactions of the
isoleucine and valine biosynthesis catalyzed by enzymes are
common to both pathways. One of the intermediates of the
valine pathway is used for the synthesis of leucine.
Therefore, inhibition of the isoleucine-valine pathway
enzymes, acetolactate synthase (ALS) and ketol acid
reductoisomerase (KARI) will result in elimination of all the
three branched-chain amino acids (US5998420) [82].
Herbicides that inhibit plant branched-chain amino acid
biosynthetic enzymes were tested for inhibition of M.
tuberculosis growth in vitro [83, 84]. Sulphometuron methyl
and metsulphuron methyl, inhibitors of ALS, were indeed
able to affect the growth of M. tuberculosis. Furthermore,
inhibitors of both ALS and KARI were effective against
drug-resistant clinical isolates. Animal studies showed that
sulphometuron methyl significantly prevented the growth of
M. tuberculosis in lungs [85]. As mammals do not have
branched-chain amino acid biosynthetic enzymes, treatment
with these compounds should be specific to pathogenic
organism. US patent no. 5998420 issued in 1999, patent
applications AU2451397 and WO9737660 published in 1997
relate to a method for treating tuberculosis by administering
therapeutically effective amount of a compound that inhibits
an enzyme of the branched chain amino acid biosynthetic
pathway in M. tuberculosis [82, 86, 87].
Thymidylate synthase is a ubiquitous enzyme, which
catalyzes the essential methylation of dUMP to dTMP, one
of the four bases required for DNA synthesis. The reaction
requires N5, N10-methylene H4 folate as a cofactor.
Thymidylate synthase activity is strongly linked to the
activity of the two enzymes responsible for replenishing the
cellular folate pool: Dihydrofolate reductase and Serine
transhydroxymethylase. Thymidylate synthase of M.
tuberculosis (Rv2492) has been cloned and characterized
(WO02072805) [88]. The thymidylate synthase reaction is a
crucial part of the pyrimidine biosynthesis pathway, which
generates dCTP and dTTP for incorporation into DNA.
Inhibition of dTMP synthesis leads to a loss of DNA
production, an arrest of the cell cycle and eventually a
'thymine-less' cell death. The emergence of multi-drug
resistant bacteria in recent years has prompted research into
the use of mycobacterial thymidylate synthase inhibitors as
antibiotics. WO02072805 published in 2002 relates to the
identification of a novel protein, thymidylate synthase and its
use in the diagnosis, prevention and treatment of disease.
Moreover, thymidylate synthase has been implicated in the
pathogenicity of the M. tuberculosis and the ligands of this
protein are likely to be effective in controlling disease.
Macrophages produce nitric oxide and other reactive
nitrogen intermediates (RNI) to control infection by M.
tuberculosis [89]. Despite the protective effect of RNI,
mycobacteria persist and multiply in macrophages. Genes
required for resistance against host RNI were identified
using transposon mutagenesis and the mutants were screened
for hyper susceptibility to acidified nitrite [90]. The study
yielded seven genes with transposon insertions, including the
genes required for DNA repair (uvrB) and synthesis of a
flavin cofactor (fbiC) (US2004213776) [91]. Five mutants
had insertions in two proteasome-associated genes that
encode a proteasome-associated adenosine triphosphatase
(ATPase) called Mpa (Rv2115c) and a proteasome-
associated factor called Paf (Rv2097c) [90, 91]. Unlike wild
type M. tuberculosis, mutants (Rv2115c and Rv2097c) failed
to grow in resting primary macrophages isolated from wild
type or iNOS -/- mice. An inhibitor of the human proteasomal
protease, N-[4-morpholine]carbonyl-b -[1-naphthyl]-L-
alanine-L-leucine boronic acid blocked proteosomal protease
activity in M. tuberculosis  and suppressed the growth of M.
tuberculosis in culture conditions [90]. A specific inhibitor
of bacterial proteasome might be useful to sensitize M.
tuberculosis to the immune system if they are combined with
chemotherapeutic agents that target enzymes involved in
RNI resistance. US2004213776 published in 2004 provides
methods for screening compounds that inhibit proteasomal
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and protease activity, DNA repair enzyme activity, or flavin-
like co-factor synthesis enzyme activity, where the inhibitory
compounds have an ability to sensitize bacteria to the
antibacterial effects of oxidative/nitrosative stress.
ENZYMES INVOLVED IN VIRULENCE AND
PERSISTENCE
M. tuberculosis virulence can be understood by finding
the factors that are important for the progression of
tuberculosis. In most cases, essentiality of these factors for
virulence has been studied either by gene knockout, global
gene inactivation by transposon mutagenesis or antisense
strategy. Understanding the strategies employed by M.
tuberculosis for persistence would allow designing of
antibiotics or inhibitors that would specifically target
persistent or latent bacilli, allowing shortening of time
required for chemotherapy.
Hypoxia is proposed as a key signal sensed by mycobac-
terium to enter into the persistent state [92]. Importantly, the
dormant form of the bacterium is resistant against
conventional antimycobacterials [93, 94]. To identify genes
induced in dormancy, Boon et al. subjected M. bovis BCG to
an oxygen-limited Wayne culture system followed by
proteome analysis. Their work revealed the up-regulation of
response regulator Rv3133c and three other polypeptides: a -
crystallin and two “conserved hypothetical” proteins,
Rv2623 and Rv2626c (WO0248391) [95]. The gene
encoding response regulator DevR (Rv3133c/DosR) has
been shown to be involved in virulence of M. tuberculosis as
discussed earlier. DevR, a transcriptional regulator, also
regulates the expression of three other dormancy genes [96].
Thus, the dormant mycobacterium can be targeted by
inhibitors of DevR, leading to down regulation of Rv2623
and Rv2626c. WO0248391 (2002) and US2004 242471
(2004) disclose a method for the identification of an anti-
mycobacterial agent that modulates the activity and/or
expression of a protein (Rv3133c, Rv2623 and Rv2626c)
expressed by a mycobacterium in non-oxygen limiting
stationary phase, hypoxic stationary phase or hypoxic growth
phase [95, 97].
As discussed above, the drugs available against
tuberculosis are unable to eliminate dormant bacilli. The
persistent bacilli can get reactivated and cause disease
following immune system perturbations. The resuscitation of
dormant bacilli would make the bacterium susceptible to
anti-mycobacterial drugs and would lead to successful
elimination of dormant bacilli. The discovery of new class of
pheromones, which stimulate the resuscitation of dormant
bacilli has provided opportunities for treatment of persistent
mycobacterial infection. Resuscitation factor (Rpf) is a
secreted growth factor, which is required for the growth of
vegetative cells in minimal media at very low inoculum
densities, as well as for the resuscitation of dormant cells. M.
tuberculosis contains five genes whose predicted products
resemble Rpf from Micrococcus luteus (WO9855624) [98].
The Rpf-like proteins of M. tuberculosis (RpfA-E) were
cloned and were shown to stimulate bacterial growth in
laboratory culture at picomolar concentrations [99]. The Rpf-
like proteins of M. tuberculosis show cross-species activity
as they were shown to stimulate the growth of the slow-
growing organism, M. bovis BCG and two fast-growing
organisms, M. smegmatis and M. luteus . Moreover, expres-
sion of Rpf in M. smegmatis could also stimulate its growth
in minimal medium [99]. WO9855624 published in 1998
describes Rpf, their cognate receptors and inhibitors or
mimetics. Pharmaceutical compositions and methods based
on the Rpf and their receptors/convertases are also described
in the patent.
Zhang et al. have also shown that dormant bacilli can be
resuscitated by spent culture supernatant [100]. The compo-
nents present in the culture supernatant having resuscitation
activity were found to be phospholipids and peptide
fragments of Rv1174c (WO0245736) [101]. Phosphatidyl-L-
serine and a dioleoyl phosphatidyl-L-serine, both of which
are precursors of phosphatidylethanolamine and phos-
phatidylcholine had significant resuscitation activity for the
6-month-old M. tuberculosis H37Ra cells over medium
control as judged by colony forming units (CFU) assay.
Phosphatidyl-L-serine allowed small inocula (10-7 dilution)
to form visible growth and CFU on plates, whereas the
control culture grew only at 10-5 dilution. Taken together,
these results suggest that the phospholipids not only
resuscitated old tubercle bacilli but also allowed small
inocula to initiate growth in liquid culture. MALDI mass
spectroscopic analysis of culture supernatant fractions and
N-terminal amino acid sequencing revealed a peptide
identical to the 29th to 58th aminoacids of a hypothetical
protein Rv1147c of M. tuberculosis with unknown function
[100]. WO0245736 published in 2002 provides the media for
growth enhancement and resuscitation of mycobacteria. In
this patent, diagnostic kits and treatment methods utilizing
spent culture supernatant and cell extracts are also provided.
Alkyl hydroperoxide reductase, subunit C (AhpC) of M.
tuberculosis (MtAhpC, WO9954479) [102] is a member of
peroxidases, the peroxyredoxins found in many organisms.
MtAhpC can detoxify hydroperoxides and protect against
reactive nitrogen intermediates [103, 104] and specifically
catalyzes the conversion of peroxynitrite (OONO-) to nitrite
[105]. Enhanced expression of MtAhpC is observed both in
INH resistant KatG-deficient strains [106] as well as in INH-
sensitive strains when challenged with the drug [107]. The
crystal structure of Cys176-Ser point mutant of MtAhpC
suggested a model for the peroxidase reaction that includes
the generation of a large internal cavity, which encloses the
reaction center [108]. The intricacies of the mechanism
supported by the structural details might provide a structural
framework for the design of inhibitors with potential
therapeutic applications. MtAhpC together with AhpD,
dihydrolipoamide dehydrogenase, and dihydrolipoamide
succinyltransferase (US2003190325) comprise an NADH-
dependent peroxidase and peroxynitrite reductase system,
which provides support to the antioxidant defense of M.
tuberculosis [109, 110]. The AhpD crystal structure revealed
a trimer with two catalytic sulfhydryl groups; Cys-130 and
Cys-133, in which each of the subunits had an identical but
novel protein fold [111]. Structural details can support for
designing inhibitors with potential utility as antitubercular
agents. WO9954479 published in 1999 relates to the use of
alkyl hydroperoxide reductase subunit C encoding gene,
proteins or polypeptides to confer resistance against
antimicrobial reactive nitrogen intermediates. AhpC can be
used to screen drugs that inhibit the activity of AhpC and
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sensitize M. tuberculosis to RNI produced by host cells.
Alternatively, therapeutics can be developed to treat gastric
infection. AhpC can be useful in vaccines to prevent
infection by M. tuberculosis, while the antibodies raised
against this protein can be employed in passive
immunization of infected person. These proteins, antibodies
and DNA molecules may also be utilized in diagnostic
assays to detect M. tuberculosis in tissue or body fluids.
US2003190325 published in 2003 relates to the methods of
inhibiting AhpD, dihydrolipoamide dehydrogenase and
dihydrolipoamide succinyltransferase in the infected person
to make the pathogen susceptible to antimicrobial reactive
nitrogen intermediates or reactive oxygen intermediates.
Methods of producing an AhpD crystal suitable for X-ray
diffraction as well as methods for designing a compound
suitable for treatment or prevention of tuberculosis are also
disclosed.
During infection, many pathogens encounter deprivation
of certain essential nutrients and cofactors. Mutations in the
genes encoding enzymes in the biosynthetic/degradative
pathways and acquisition systems for some of these factors
have helped in deciphering new drug targets. Earlier it has
been reported that M. tuberculosis shifts from a metabolism
that preferentially uses carbohydrate when growing in vitro
to one that utilizes fatty acids when growing in the host,
which is supported by the fact that over 200 genes were
annotated to be involved in fatty acid metabolism [9]. One
such enzyme is isocitrate lyase (Icl, WO0233118) [112] that
converts isocitrate to succinate in the glyoxylate shunt and
thus helps to survive on acetate or fatty acids as the sole
carbon source. Icl activity increases dramatically in the
stationary phase of M. tuberculosis growth [113] and its
mRNA levels increase during macrophage infection and in
the lungs of infected mice [114-116]. It has also been
demonstrated that Icl is important for survival of M.
tuberculosis in the lungs of mice during the persistent phase
of infection (2-16 weeks), but is not essential during the
acute phase (0-2 weeks) [117]. Given its potential as a drug
target against persistent infections, its structure was solved
without ligand and in complex with two inhibitors [118].
Covalent modification of an active site residue, Cys 191, by
the inhibitor 3-bromopyruvate traps the enzyme in a catalytic
conformation with the active site completely inaccessible to
solvent. These inhibitor-bound structures not only help to
establish key residues in the active site, but enable to
pinpoint interactions, which are essential in forming the
closed conformation of the enzyme and are likely to be a key
to successful drug discovery. WO0233118 published in 2002
discloses the importance of the glyoxylate shunt in the
persistent phase of various infectious agents, including
mycobacteria and the identification of targets for drug
development. Crystals and three-dimensional structures of
M. tuberculosis  Icl, without ligand and in complex with two
inhibitors that can be used in the design of inhibitors and
therapeutic agents are also disclosed.
Protein export is an important aspect of bacterial
pathogenesis. Research on diverse bacterial pathogens has
demonstrated that the majority of virulence factors are
secretory proteins [119, 120]. In bacteria, the majority of
exported proteins are translocated by the Sec system, which
recognizes the signal sequence of a pre-protein and uses ATP
and the proton motive force to mediate protein translocation
across the cytoplasmic membrane. SecA (WO9626276)
[121] is an essential protein component of this system,
containing the molecular motor that facilitates translocation.
There are two homologues of secA in mycobacteria, secA1
and secA2. Using an allelic-exchange strategy in M.
smegmatis, it was demonstrated that secA1 is the essential
housekeeping protein whereas secA2 is an accessory factor
for the secretion [122]. The topography of SecA of M.
tuberculosis and its ATP binding sites are highly conserved,
whereas its membrane insertion domains are species specific
[123]. The crystal structure of SecA1 revealed that each
subunit of the homodimer contains a motor domain and a
translocation domain. The structure predicts that SecA can
interact with the SecYEG pore and function as a molecular
ratchet that uses ATP hydrolysis for physical movement of
the preprotein [124]. A deletion of the secA2 gene in M.
tuberculosis led to loss of virulence because SecA2 mediates
secretion of SodA, a virulence factor of M. tuberculosis
[125]. WO9626276 published in 1996 relates to an isolated
nucleic acid encoding a SecA protein of M. tuberculosis. The
invention includes the mutant SecA protein of M.
tuberculosis and provides methods of screening for putative
virulence factors translocated by SecA.
CURRENT AND FUTURE DRUG DEVELOPMENTS
The availability of M. tuberculosis  genome sequence [9]
and recent advances in understanding the molecular basis of
host pathogen interaction have opened new avenues for the
development of novel antimycobacterial drugs. Promising
new drug candidates such as PA-824 (nitroimidazopyran)
have entered phase I clinical trials (www.tballiance.org). PA-
824 exhibits bactericidal activity against both actively
growing and static M. tuberculosis . The potency of PA-824
is attributed to its ability to get activated by M. tuberculosis
F420 cofactor and inhibit the synthesis of protein and cell
wall lipid [126-128]. Diarylquinoline (R207910), another
molecule reported by Johnson and Johnson Pharmaceutical
Research and Development, has a unique spectrum of potent
and selective anti-mycobacterial activity under in vitro
conditions. The molecule is active against both drug-
sensitive and drug-resistant M. tuberculosis and it was
suggested that the drug targets the proton pump of adenosine
triphosphate (ATP) synthase [129]. Plasma levels associated
with efficacy of R207910 in mice were well tolerated in
healthy human volunteers. Another drug, tetrahydroben-
zothiophene (AX20017) developed by Axxima Pharma-
ceuticals AG, Germany, was shown to inhibit the kinase
activity of PknG of M. tuberculosis. Chemical targeting of
PknG led to the localization of  M. bovis BCG into lysosomes
causing bacterial lysis within macrophages [70]. AX20017
represents a promising candidate for the development of a
class of drugs that would target the intracellularly residing
mycobacteria.
In the past several years, it has been realized that
controlling tuberculosis needs two issues to be addressed,
drug resistance and persistence. A better understanding of
the biology of tubercle bacilli, development in mycobacterial
genetic tools, high throughput drug screening and structure
based drug designing have increased the prospect of
identifying novel anti-tubercle agents to combat drug
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resistant and persistent organisms. In short, investigation of
M. tuberculosis pathogenesis has entered a new era and it is
anticipated that the global challenge of tuberculosis will be
surmounted in near future.
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